Bio-Rad Laboratories, Inc. (BIO-B) Stock Price & Analysis
Bio-Rad Laboratories, Inc. (BIO-B) closed at USD 364.15 on Wednesday, October 14, 2026, up 0.00% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 364.15; the Oct 14, 2026 session ranged USD 364.15–364.21 on volume of 8 shares. Market capitalization is $9.74B, with a 52-week range of USD 244.54–365.08 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BIO-B.md
Key facts (BIO-B)
- Last four reported quarters (through Jun 30, 2026): revenue $2.59B, net income $222M (8.6% margin), free cash flow $353M (SEC filings).
- Valuation: P/E 43.8x (avg 11.2x at the last 1 fiscal year-ends), net cash $415M.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $136K; 1 not under a Rule 10b5-1 plan ($136K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: None.
- Total return with dividends: 1Y +13.4% vs S&P 500 +14.9%; 5Y -50.1% vs S&P 500 +80.3%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BIO-B)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B | $2.59B |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B | — |
| Operating income | $500M | $483M | $338M | $269M | $47.2M | $53.1M |
| Net income | $4.25B | -$3.63B | -$637M | -$1.84B | $760M | $222M |
| EPS (diluted) | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 | — |
| Free cash flow | $536M | $81.6M | $218M | $290M | $375M | $353M |
| Gross margin | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% | — |
| Operating margin | 17.1% | 17.2% | 12.6% | 10.5% | 1.8% | 2.1% |
| Net margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% | 8.6% |
| Revenue growth | +14.8% | -4.1% | -4.7% | -3.9% | +0.7% | — |
| Cash + short-term investments | $870M | $1.79B | $1.61B | $1.66B | $1.54B | — |
| Total debt | $10.5M | $1.20B | $1.21B | $1.20B | $1.20B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BIO-B)
P/E 43.8x · P/S 3.8x · EV/Sales 3.6x · P/FCF 27.6x · P/B 1.4x · FCF yield 3.63% · Earnings yield 2.28% · Buyback yield (TTM) 1.36% · Net cash $415M · EV $9.32B
P/E at fiscal year-ends: Dec 2025 11.2x.
Insider sales (SEC Form 4, open-market, last ~7 months) (BIO-B)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Engelhardt Eva Anette | EVP, President, CDG | 550 | $136K | 61.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BIO-B)
Consensus None.
Total return (dividends reinvested) (BIO-B)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +13.4% | -50.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +13.4% | -13.0% |
| Volatility (annualized) | 31.4% | 34.6% |
| Max drawdown | -20.4% (Oct 2025→May 2026) | -70.7% (Nov 2021→Apr 2025) |
Companies that name BIO-B in their SEC reports
| Relationship to BIO-B | Company | Filing | Sentence |
|---|---|---|---|
| partner | Insight Molecular Diagnostics Inc. (IMDX) | 10-K Mar 26, 2026 | “our dependency on our collaboration with Bio-Rad Laboratories, Inc. for the development and commercialization of products;” |
| customer | BIODESIX INC (BDSX) | 10-K Feb 26, 2026 | “For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see "Business—Material Agreements—Agreements with Bio-Rad" filed with our Form S-1 on October 23, 2020 and "First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021" filed with our Form 10-Q on August…” |
BIO-B analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $650.0M | — |
| Next quarter (ends Dec 2026) | — | — | — | $695.4M | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $2.57B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $2.62B | — |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 364.15 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 364.15 |
| Open | USD 364.21 |
| Day Range | USD 364.15 – 364.21 |
| 52-Week Range | USD 244.54 – 365.08 |
| Volume | 8 shares |
| Market Cap | $9.74B |
| Exchange | NYQ |
Technical Analysis (BIO-B)
Nexqual's technical model rates BIO-B "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Above (USD 362.14) |
| MACD | 0.98 (positive) |
Analyst Ratings (BIO-B)
Wall Street analysts rate BIO-B "None", per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | None |
|---|
Earnings (BIO-B)
| Revenue Estimate | $649.95M |
|---|
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (BIO-B)
| Total Revenue | $2.59B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -0.10% |
| Gross Margin | +52.04% |
| Operating Margin | +11.18% |
| Profit Margin | +8.59% |
| ROE | +3.11% |
| Debt / Equity | 0.19 |
| Current Ratio | 3.14 |
| Total Cash | $1.62B |
| Total Debt | $1.37B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $353.10M (13.6% of revenue) |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (BIO-B)
Nexqual rates Bio-Rad Laboratories, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — Revenue +0.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 52%, operating 11% (last 12 months) |
| Balance Sheet | Strong — $1.62B cash and investments vs $1.20B debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $353M (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Weak — ROE 3%, ROA 1.7% |
Ownership (BIO-B)
| Insider Ownership | +98.23% |
|---|---|
| Institutional Ownership | +0.04% |
| Shares Outstanding | 5.06M |
| Float | 21.35M |
| Short % of Float | +0.00% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (BIO-B)
Bio-Rad Laboratories, Inc. is led by Norman D. Schwartz, Chairman & CEO, per Nexqual as of October 23, 2026 at 10:12 UTC.
| Chairman & CEO | Norman D. Schwartz |
|---|---|
| President & COO | Jonathan P. DiVincenzo |
| Executive VP & CFO | Roop K. Lakkaraju |
| Executive VP & President of Life Science Group | James J. Barry |
| Executive Vice President of Global Commercial Operations | Rajat Mehta |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PODD | Insulet Corporation | USD 148.12 | ▲ 4.38% |
| TXG | 10x Genomics, Inc. | USD 69.75 | ▼ 7.73% |
| GKOS | Glaukos Corporation | USD 176.69 | ▼ 0.09% |
| BRKR | Bruker Corporation | USD 57.31 | ▼ 3.05% |
| GMED | Globus Medical, Inc. | USD 81.66 | ▲ 3.79% |
| SNN | Smith & Nephew SNATS, Inc. | USD 30.88 | ▲ 5.64% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt